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Abstract
LHX4 is a LIM homeodomain transcription factor involved in the early steps of pituitary onto-
genesis. To date, 8 heterozygous LHX4mutations have been reported as responsible of
combined pituitary hormone deficiency (CPHD) in Humans. We identified 4 new LHX4 het-
erozygous allelic variants in patients with congenital hypopituitarism:W204X, delK242,
N271S andQ346R. Our objective was to determine the role of LHX4 variants in patients’
phenotypes. Heterologous HEK293T cells were transfected with plasmids encoding for
wild-type or mutant LHX4. Protein expression was analysed by Western Blot, and DNA
binding by electro-mobility shift assay experiments. Target promoters of LHX4 were
cotransfected with wild type or mutant LHX4 to test the transactivating abilities of each vari-
ant. Our results show that theW204Xmutation was associated with early GH and TSH defi-
ciencies and later onset ACTH deficiency. It led to a truncated protein unable to bind to
alpha-Gsu promoter binding consensus sequence. W204X was not able to activate target
promoters in vitro. Cotransfection experiments did not favour a dominant negative effect. In
contrast, all other mutants were able to bind the promoters and led to an activation similar
as that observed with wild type LHX4, suggesting that they were likely polymorphisms. To
conclude, our study underlines the need for functional in vitro studies to ascertain the role of
rare allelic variants of LHX4 in disease phenotypes. It supports the causative role of the
W204Xmutation in CPHD and adds up childhood onset ACTH deficiency to the clinical
spectrum of the various phenotypes related to LHX4mutations.
Introduction
Pituitary ontogenesis requires a precise temporal and spatial regulation of several early and
late-acting transcription factors, such as LIM (LIN-11, Isl1 and MEC-3) domain transcription
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factors (LHX4, LHX3, LHX2 or ISL1)[1, 2]. In Humans, mutations of some of the genes coding
for these transcription factors lead to combined pituitary hormone deficiency (CPHD)[3].
CPHD is a rare condition defined by the presence of at least two anterior pituitary hormone
lineage deficiencies, associated with variable pituitary and extra-pituitary anomalies on MRI.
Lhx4 is specifically involved in the early steps of pituitary ontogenesis[4–6]. Although the
roles of Lhx4 might be redundant at some developmental stages with those of Lhx3 (4)(6),
proper expression of Lhx4 is crucial not only for the development of the rudimentary Rathke’s
pouch into the mature pituitary, but also for the development of other organs such as the
lungs. Murine models indeed showed that Lhx4 homozygous inactivation (lhx4-/-) led to an
early death due to pulmonary failure: mice presented hypoplastic Rathke’s pouch with a de-
creased number of the precursors of the five anterior pituitary lineages. In contrast, mice with
Lhx4 heterozygous inactivation (lhx4+/-) had a normal phenotype[7].
In humans, LHX4mutations are rare[8, 9]. In our cohort of patients with CPHD, only 3
mutations have been reported among the 321 patients screened to date in view of compatible
phenotypic profiles (unpublished data). Since the first reported LHX4mutation, advances have
been made on the phenotypic characterization and outcome of patients carrying LHX4muta-
tions. We and others have for instance emphasized the large intra- and inter- familial variabili-
ty of the phenotype. Precise profile of patients to be screened for mutations of LHX4 remains
difficult to determine, as only eight LHX4mutations transmitted as an autosomal dominant
trait have been reported in the literature [8, 10–14]. Patients were presenting with CPHD, but
the number and nature of deficient pituitary lineages were variable; extra-pituitary anomalies
could be absent or include ectopic posterior pituitary, abnormal sella turcica shape or abnormal
corpus callosum.
Four new LHX4 allelic variants have been found in five distinct pedigrees through the GEN-
HYPOPIT network, an international network that collected DNA samples and phenotype data
from more than 1000 patients with CPHD. We report here the phenotypes of the patients, the
results of the functional studies, and extend the genetic and phenotypic spectrum of LHX4mu-
tations. Our results also raise the difficulties in proving the deleterious effect of unknown
allelic variants.
Materials and Methods
Subjects
The GENHYPOPIT network was launched as a multicentric study involving both French and
international pediatric and adult endocrinology centers. Screening of LHX4mutations was per-
formed in patients with specific phenotypes as previously described (8). Hormonal studies and
intracranial imaging were performed in all patients in each referring medical center. On MRI,
malformations were systematically sought and recorded. Patients with a known postnatal
cause of acquired hypopituitarism were excluded. After written informed consent was given,
blood samples were collected from patients and, whenever possible, first-degree relatives. In-
formed written consent was obtained from the parents, caretakers or guardians on behalf of
the minor/children enrolled in the study. The study was approved by the Ethics committee of
the University of Aix-Marseille II (France).
Screening for LHX4mutations
LHX4 sequence was amplified from perip heral blood DNA. Genomic analysis of LHX4 was
performed by direct sequencing. The six coding exons of LHX4 were amplified from genomic
DNA using exon-flanking primers as previously described [8]. The same primers were used for
sequencing using CEQ 8000 sequencer (Beckman Coulter, Fullerton, CA). According to the
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previously described genotyping algorithm (13), other candidate genes (HESX1, OTX2,
PROKR2, LHX3, SOX3, PROP1) had previously been sequenced in the patients, and no alter-
ation had been found in coding regions.
In silico analyses
Alignment of amino acid sequences was performed with Clustal X (www.clustal.org) and Phy-
logene (acces.ens-lyon.fr/biotic/evolut/phylogene/accueil.htm) softwares. Poliphen 2 (http://
genetics.bwh.harvard.edu/pph2), Predict SNP (http://loschmidt.chemi.muni.cz/predictsnp)
and UMD-HTS (www.umd-hts.eu/WHTS9), were used to appraise the potential pathogenicity
of each allelic variant.
Plasmid constructs and mutagenesis
pcDNA3.1 LHX4-myc plasmid was a gift from S. Rhodes (Indianapolis, USA). In vitro site-di-
rected mutagenesis was performed using the QuikChange Site-Directed Mutagenesis System
(Stratagene cloning system, La Jolla, CA). In brief, 100-ng template DNA was incubated with
Accuprime DNA polymerase (Invitrogen, France) and the sense and antisense primers con-
taining the desired mutation. The reaction comprised 18 cycles consisting of 15 sec denatur-
ation at 95°C, 30 sec annealing at 55°C, and 6.5 min extension at 68°C. After purification
(NucleoSpin plasmid Miniprep kit, Macherey-Nagel) and amplification of the mutated plasmid
the correct sequence was confirmed by sequencing. Notice that due to the truncated nature of
the protein encoded byW204X LHX4, a specific primer design had to be considered to keep
the myc C-terminal tag in frame. Mutagenesis primers used for each allelic variant are available
on request.
Reporter constructs containing different gene-regulatory regions with putative LIM factor
binding sites were fused to a firefly luciferase gene. These constructs included the proximal
promoter regions of the human PRL gene (PRL-250) (a gift of J. A. Martial, Liege, Belgium),
the proximal promoter regions of the human TSHb gene (a gift of S. Amselem, Paris, France),
the proximal promoter regions of the human alpha-subunit (αGSU) gene (a gift of S. Amselem,
Paris, France) and the positive autoregulatory site of the human POU1F1 promoter gene (a gift
of M. Delhase, Libe, Bruxelles, CA) (19).
Western Blot
For Western Blot analyses of cells transfected with LHX4 expression vectors nuclear extracts
were prepared, and were run on a 12% acrylamide gel (25 μg protein per lane). After transfer,
nitrocellulose membrane (iBlot Gel transfert, Invitrogen) was incubated with the primary anti-
body (1/1000, Mouse anti-myc antibody, clone 9E10 ThermoFisher Scientific), followed by the
secondary antibody (anti-mouse rabbit polyclonal antibody at 1/10 000, Santa Cruz biotech-
nology inc Texas, USA).
EMSA
EMSA experiments were performed using the previously described LUEGO technique(14)
with probes representing the pituitary glycoprotein basal element (PGBE) of the αGSU gene,
labeled with fluorophore CY5 (5'-gtgccctggtctgg ggtacttagctaattaaatgtg-3 ‘; 3'-cacgggaccagaccc
catgaatcgattaatttacac-5'). Fifteen μg of nuclear protein extracts were used. Supershift assay was
performed with 0.5 μg of mouse anti-myc antibodies. Depending on condition, unlabeled wild-
type (wild competitor) or mutated (mutated competitor, 5’-ggtacttagctaactgactgtg-3’) probes
LHX4 Variants in Human Pituitary Deficiency
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were used as competitors (50-fold higher concentration). Visualization was performed with
Typhoon FLA 9000 scanner (GE Healthcare).
Cell culture and transfection
HEK293T cells were cultured in 12-well plate and transfected as follows: 200 ng reporter con-
structs (TSHb, PRL-250, AlphaGsu, or POU1F1 promoter) and 200–400 ng effector construct
(pcDNA3.1 empty vector or wild- type or mutant LHX4) per well were cotransfected using the
liposome technique (Polyfect transfection reagent; QIAGEN, Hilden, Germany). Total DNA
was kept constant with pcDNA3.1 empty vector, which also acted as a control. Transfection ef-
ficiency was determined using 15 ng pCMV-Renilla, and used to normalize the luciferase firefly
values. Firefly and Renilla luciferase activity was measured 48 h after transfection. All experi-
ments were repeated thrice, and all assay points were performed in triplicate. Results are ex-
pressed in relative units (fold increase vs. empty vector).
Statistical analysis
Data points were compared using a one-tailed Student's t-test for paired samples using XLStat
2013.4.05 (Paris, France). Values were considered significantly different when p<0.05.
Results
Individual data of the patients bearing LHX4 allelic variants
Pedigree A: Trp204X LHX4 allelic variant. The propositus was referred to an endocrinol-
ogist at the age of two years because of growth delay. TSH and GH deficiencies were diagnosed
and the patient received L-thyroxin and GH replacement therapy. Corticotroph deficiency was
diagnosed later, at the age of nine, as the patient was suffering from asthenia. Hydrocortisone
was therefore initiated (20 mg/day). Due to the prepubertal age of the propositus, FSH/LH defi-
ciency was not evaluated. Pituitary MRI, performed at the age of two, showed a hypoplastic pi-
tuitary, and an ectopic posterior lobe. The pituitary stalk was not visualized. No extra-pituitary
malformation was found.
Genetic analyses showed that the propositus was bearing the allelic variant p.W204X in a
heterozygous state. His parents, older sister and younger brother were clinically unaffected and
no genetic analysis could be performed.
Pedigree B: DelLys242 LHX4 allelic variant. ACTH, TSH and GH deficiencies were diag-
nosed at the age of one month because of a prolonged jaundice. Due to the prepubertal age of
the propositus, FSH/LH and testosterone were evaluated at 2 months of age, and presented a
normal pattern throughout post-natal gonadotropic surge. Pituitary MRI showed a hypoplastic
pituitary with a normal pituitary stalk and posterior pituitary lobe.
Genetic analyses showed that the propositus was bearing the allelic variant p.DelK242 in a
heterozygous state. His mother, who did not have any pituitary deficiency and had normal pi-
tuitary MRI, was also carrying the same allelic variant. No other family member was available.
Pedigree C: Asn271Ser LHX4 allelic variant. The propositus was born with cleft lip and
palate. She had growth retardation since the first year of life and GH deficiency was diagnosed
at 2 years. Central hypothyroidism was diagnosed at 3 years of age. Pituitary MRI showed hy-
poplastic anterior pituitary and an ectopic posterior lobe. The pituitary stalk was not
visualized.
Genetic analyses showed that the propositus was bearing the allelic variant p.N271S in a het-
erozygous state. No other family member was available.
LHX4 Variants in Human Pituitary Deficiency
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Table 1. Phenotypic and biological profiles of the patients bearing the four new allelic variants.
Mutation W204X DelK242 N271S Q346R Q346R
Year of birth 2001 2005 2003 1996 1983
Country France Argentina Argentina France Slovenia
Medical history of hypopituitarism in family No No Not speciﬁed No Not speciﬁed
ACTH deﬁciency Yes (9 yrs) Yes (0.1 yr) No NO Yes (18 yrs)
TSH deﬁciency Yes (2 yrs) Yes (0.1 yr) Yes (3 yrs) Yes (10 yrs) Yes (10 yrs)
FSH/LH deﬁciency NE NE No No Yes (15 yrs)
GH deﬁciency Yes (2 yrs) Yes (0.1 yr) Yes (2 yrs) Yes (6 yrs) Yes (10 yrs)
Anterior pituitary on MRI Hypoplastic Hypoplastic Normal Hypoplastic Hypoplastic
Posterior pituitary MRI Ectopic Not speciﬁed Ectopic Ectopic Ectopic
Pituitary stalk MRI Not visualized Not speciﬁed Thin Not visualized Not visualized
Associated malformations No No Cleft lip and palate Hypospadias, toe agenesis, short limb No
For pituitary deﬁciencies, data between brackets represent age at diagnosis. Complete GH deﬁciency was deﬁned as GH response after stimulation below
10 mUI/liter. Corticotroph deﬁciency was deﬁned as plasma cortisol value below 500 nmol/liter after insulin test stimulation. Gonadotroph axis was
investigated only in patients of postpubertal age, ie. older than 15 years for female and 17 years in male subjects. FSH-LH deﬁciency was diagnosed on
the basis of delayed or absent pubertal development with low serum testosterone or estradiol levels and blunted LH/FSH response to a GnRH stimulation
test. Thyrotroph deﬁciency was deﬁned as low or normal basal TSH levels associated with low T4 levels. NE, not evaluated.
doi:10.1371/journal.pone.0126648.t001
Fig 1. Schematic representation of LHX4 (true length of each domain was not considered). Upper part: Previously published mutations considered
pathogenic on the basis of transfection studies (9)(10)(11)(8). Note that intronic mutations are not shown(9)(12). Lower part: Newly identified allelic variants in
this study. HD: homeodomain. Aminoacids 30–84, first LIM domain; aminoacids 88–150, second LIM domain; aminoacids 155–215, homeodomain (HD).
doi:10.1371/journal.pone.0126648.g001
LHX4 Variants in Human Pituitary Deficiency
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Pedigrees D and E: Gln346Arg LHX4 allelic variant. This allelic variant was found in two
unrelated patients:
Pedigree D:
The patient presented complete GH deficiency at the age of six and TSH deficiency at the
age of ten. He had hypospadias, toe agenesis and a short limb. Pituitary MRI showed a hypo-
plasic pituitary and an ectopic posterior lobe. The pituitary stalk was not visualized. Genetic
analyses showed that the propositus was bearing the allelic variant p.Q346R in a heterozygous
state. His parents, and younger brothers were clinically unaffected and no genetic analysis
could be performed.
Pedigree E:
The patient presented TSH and GH deficiencies at the age of 10, ACTH and LH/FSH defi-
ciencies at the age of 18. Pituitary MRI showed a hypoplastic pituitary and an ectopic posterior
lobe. The pituitary stalk was not visualized.
Genetic analyses showed that the propositus was bearing the allelic variant p.Q346R in a het-
erozygous state. No other family member was available (Table 1, Fig 1).
In silico analyses
All of the modified LHX4 amino acid residues were conserved in known LHX4 sequences in
mammalians and chicken (data not shown). Prediction softwares showed that only theW204X
Fig 2. Western Blot.Western blot analysis of wild-type and mutant LHX4 proteins from transfected heterologous human embryonic kidney 293T cells. The
migration positions of protein standards (kDa) are shown. Control is transfection with empty vector. Lanes are identified as follows: Fig. A; 1, pcDNA3.1
(empty vector); 2, LHX4WT-myc; 3, DelK242-myc; 4, N271S_myc; 5, Q346R-myc; Fig. B; A: LHX4WT-myc diluted to 1/8; B: LHX4WT-myc diluted to¼; C:
LHX4WT-myc diluted to½; D: LHX4WT-myc; E: LHX4 203-myc.
doi:10.1371/journal.pone.0126648.g002
LHX4 Variants in Human Pituitary Deficiency
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allelic variant was a likely pathogenic mutation, whereas DelK242, N271S, and Q346R allelic
variants were considered as polymorphisms.
In vitro analyses
Western Blot. When expressed in HEK 293T cells, wild-type and DelK242, N271S, and
Q346R LHX4 proteins of similar sizes (50 kDa) were detected by Western blotting (Fig 2A). As
expected, the truncated W204X protein was identified with a specific 33 kDa band. Our results
also suggest that the W204X protein could be under-expressed in comparison with wild-type
LHX4 (Fig 2B).
Electro mobility shift assay. To test the DNA binding properties of the altered LHX4 pro-
teins, we performed EMSA using probes representing the αGSU gene promoter. The delK242,
N271S and Q346R proteins, which have an intact homeodomain, bound with similar efficiency
as the wild-type protein. By contrast, and consistent with the lack of a part of the homeodo-
main, the W204X protein did not bind to the cognate probe (Fig 3).
Fig 3. Electro Mobility Shift Assay Experiments. EMSA was performed with the alphaGSU-luego2Cy5 probe, corresponding to a consensus binding
sequence of LHX4 identified on the alphaGSUmurine promoter (5'-gtgccctggtctgg ggtacttagctaattaaatgtg-3 ‘; 3'-cacgggaccagacc-ccatgaatcgattaatttacac-5').
Supershift was performed with a monoclonal anti-myc antibody. Arrow indicates position of the expected LHX4 DNA binding. Lanes are identified as follows:
1, free probe; 2, LHX4 wt (band corresponding to LHX4 identified by the arrow); 3, LHX4 wt + anti-myc antibody (supershift, no LHX4 band visualized at the
arrow level); 4, non mutated competitor (LHX4 band is not visualized, as the probe is bound by the competitor); 5, mutated competitor (LHX4 band is
visualized at the arrow level as the competitor can not bind the probe); 6, PcDNA3.1 (empty vector); 7, PcDNA3.1 + anti-myc antibody; 8, W204X; 9, W204X
+ anti-myc antibody (supershift); 10, DelK242; 11, DelK242 + anti-myc antibody (supershift); 12, N271S; 13, N271S + anti-myc antibody (supershift); 14,
Q346R; 15, Q346R + anti-myc antibody (supershift).
doi:10.1371/journal.pone.0126648.g003
LHX4 Variants in Human Pituitary Deficiency
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Transfections. Cotransfection of wild-type LHX4 with TSHb promoter resulted in a
strong stimulation of the luciferase reporter gene relative to the empty vector. No activation
was observed with theW204Xmutant. Cotransfection of mutantW204X and equivalent
amounts of wild-type LHX4 did not modify the effect of the latter on TSHb promoter, arguing
against a dominant negative effect. In contrast, cotransfection of DelK242, N271S or Q346R
LHX4 allelic variants with the TSHb promoter resulted in the stimulation of luciferase activity
similar to that evoked by wild-type LHX4 (Fig 4). The same results were observed for the acti-
vation of the alphaGsu, POU1F1 and prolactin promoters by the four allelic variants (data not
shown). Taken together these results suggest that DelK242, N271S and Q346R LHX4 were
probably non-deleterious polymorphisms, whereasW204X was a defective mutation.
Discussion and Conclusion
W204Xmutation represents a new pathogenic allelic variant of LHX4 found in a patient pre-
senting with combined pituitary hormone deficiency. Identification of LHX4mutations linked
to such defects have rarely been reported in the literature (8 mutations reported to date) [8–14]
and in our large GENHYPOPIT cohort of patients with CPHD (3 mutations in 321 patients
Fig 4. Expression vectors for wild-type (WT) and the four allelic variants with bTSH promoter. Plasmids expressing the various LHX4mutants were
transiently cotransfected into heterologous HEK293T cells with a luciferase reporter gene under the control of the bTSH promoter. Promoter activity was
assayed by measuring luciferase activity 48h after transfection. Negative controls (control) received equivalent amounts of empty expression vector plasmid.
Results are expressed as fold-increase of luciferase signal relative to control. *p<0.05.
doi:10.1371/journal.pone.0126648.g004
LHX4 Variants in Human Pituitary Deficiency
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screened, unpublished data). This rarity may, at least in part, be due to the fact that homozy-
gous LHX4mutations are likely lethal in Humans: this is suggested by the fact that patients
bearing LHX4mutations were always reported as heterozygous, and that mice with homozy-
gous inactivation of Lhx4 died shortly after birth[7]. Comparison with the murine model is
however difficult, as mice with heterozygous inactivation of Lhx4 are unaffected[7].
The mechanism by whichW204Xmutation leads to a functionally defective protein is an
abnormal DNA binding, as shown by the results of EMSA experiments. The functional alter-
ation induced by this new mutation could also have been due to nonsense-mediated RNA
decay. However, the mutant protein is expressed in our cells, as shown by Western blot results,
argueing against this hypothesis. Abnormal DNA binding could be expected as the protein
lacks a part of the homeodomain. We had previously reported such a mechanism for the
Thr99fs LHX4mutation (8), but the predicted truncated protein was lacking the whole homeo-
domain. Our results suggest that LHX4 amino acids 204–215, which encode for the third
DNA-recognizing alpha-helix of the homeodomain, are crucial for proper DNA binding. Con-
sistent with our results, Pfaeffle et al. had previously shown that a point mutation in this area
(A210P) also led to abnormal DNA binding[8].
Delayed corticotroph deficiency (that appeared by the age of 9) is the main striking pheno-
typic feature of our patient bearingW204Xmutation. This delayed deficiency had been re-
ported at age 16 in another patient carrying LHX4 R84Xmutation[14]. It is surprising as the
other patients with LHX4mutations had early dysfunction of pituitary lineages. However, the
father of the propositus carrying Thr99fsmutation had normal size, as did 2 children carrying
the same mutation, despite GH and LH/FSH deficiency diagnosed by the age of 40 [8]. This
suggested that delayed onset deficiencies can be observed in patients with LHX4mutations. De-
layed corticotroph, GH and TSH deficiencies have already been reported in patients carrying
mutations of PROP1, a paired homeodomain transcription factor, involved in later stages of pi-
tuitary development [15, 16]. For these 2 transcription factors, the mechanisms of delayed defi-
ciency remain however unknown [4].
Our functional studies did not show any deleterious effect of the three allelic variants
DelK242, N271S and Q346R. Despite the fact that these variants have not been identified in
SNP databases (data not shown), and that the patients were presenting with phenotypes com-
patible with LHX4mutations, our results supported their classification as rare polymorphisms
(ie. they were not responsible for the phenotype of CPHD). Of note, the delK242 variant has
been found in a heterozygous state in 3 individuals (3 out of 6259, i.e., 0.05%) from an Ameri-
can population, (see Exome Variant Server website URL: http://evs.gs.washington.edu/EVS/).
Other genes coding for transcription factors have been screened, but no clear etiology could be
identified. Other as yet unknown transcription factors or pathways might be involved in the
phenotypes. Environmental causes during pregnancy may also be involved. Another possibility
could be that our functional studies, performed in heterologous cells (chosen as they were not
expressing endogenous LHX4), in an in vitro system, and on a limited number of target genes,
did not manage to show a true defective mechanism due, for instance, to the lack of the cofac-
tors network found in pituitary cells. These results however are consistent with the fact that the
3 amino-acids were located in non-functional domains, and that in silico analysis was in favour
of silent polymorphisms. Nevertheless, defective mutations in supposedly non-functioning do-
mains have already been reported for other transcription factors: for instance, LHX3 lacking a
small part of its C-terminus domain (LHX3W224X) has been shown to be functionally defec-
tive. It can be noted also that in silico analysis is not always reliable: LHX4 V101A and A210P
mutants had indeed been considered as silent polymorphisms by prediction software, whereas
functional studies showed that they had decreased transactivating abilities on pituitary hor-
mone promoters [11, 13]. Analysing the potential pathogenic status of allelic variants by in
LHX4 Variants in Human Pituitary Deficiency
PLOS ONE | DOI:10.1371/journal.pone.0126648 May 8, 2015 9 / 11
silico analysis and on the basis of in vitro functional studies clearly suggests the need for a glob-
al approach of such new allelic variants, including both approaches, as well as disease segrega-
tion in the family: this last parameter might also be misleading, as shown by the example of the
father of the propositus carrying c.293InsCmutation who had a normal gonadotroph axis, al-
lowing him to transmit the mutation to his 2 affected children, and who finally had delayed
gonadotroph deficiency at the time of molecular diagnosis [8]. All these points clearly show the
difficulty in determining the pathogenic nature of some variants. Moreover identifying a pa-
tient with a presumed polymorphism does not rule out the need for a close monitoring over
time to allow for timely diagnosis and treatment of pituitary hormone deficits of possibly
delayed onset.
To conclude, we report here four new allelic variants of LHX4, including one unequivocally
deleterious mutation responsible for an unusual CPHD phenotype with delayed corticotroph
deficiency. The fact that the 3 other variants were identified in patients with phenotypes com-
patible with LHX4mutations emphasizes the difficulties in determining the pathogenicity of
such variants, using in vitro functional studies. Indeed, some uncertainty remains as to the ac-
curacy of such studies to predict the possible involvement of such rare allelic variations in the
observed phenotype. Identifying new etiologies of CPHD should allow improving the manage-
ment of patients with yet unknown clear explanation of their phenotype.
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